Tobias Nordström

Magnetic Resonance Imaging–based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review

Emerging tools for the early detection of prostate cancer

A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial

Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging

Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy

Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men

Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

MRI-Targeted or Standard Biopsy in Prostate Cancer Screening

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial

Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD)

Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden

Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential

Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging

Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer

Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study

The risk of prostate cancer for men on aspirin, statin or antidiabetic medications

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer

A Genetic Score Can Identify Men at High Risk for Prostate Cancer Among Men With Prostate-Specific Antigen of 1–3 ng/ml

Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003–2011